International Centre for Diarrhoeal Disease Research, Bangladesh

About: International Centre for Diarrhoeal Disease Research, Bangladesh is a facility organization based out in Dhaka, Bangladesh. It is known for research contribution in the topics: Population & Vibrio cholerae. The organization has 3103 authors who have published 5238 publications receiving 226880 citations. The organization is also known as: SEATO Cholera Research Laboratory & Bangladesh International Centre for Diarrhoeal Disease Research.

Measles vaccination and childhood mortality in rural Bangladesh

Abstract: To ascertain whether measles vaccination was associated with reduced mortality rates in rural Bangladeshi children, the authors conducted a case-control study in four contiguous areas, two of which had participated in an intensive measles vaccination program which began in the spring of 1982. Cases were 536 children who had died in the four-area region at the age of 10-60 months between April 1982 and December 1984. Two age- and sex-matched controls were selected from the four-area region for each case; each control had survived at least through the date of death of the matched case. Measles vaccination was associated with a 36% (95% confidence interval 21%-48%) proportionate reduction in the overall rate of death and a 57% (95% confidence interval 43%-67%) reduction in the rate of deaths directly attributed to measles or ascribed to diarrhea, respiratory illness, or malnutrition. The association of measles vaccination and reduced mortality remained unchanged after the authors restricted controls to children who had survived at least one year after the deaths of their matched cases. Moreover, children vaccinated in 1982 exhibited a sustained reduction in the rate of death in 1983 and 1984. The authors concluded that measles vaccination was associated with a pronounced and sustained reduction in the rate of death among children in this study.

The Bangladesh Fertility Decline: An Interpretation

Abstract: Bangladeshs fertility transition has attracted more theoretical interest than any other contemporary transition. Among countries where there has not been a coercive government family planning program Bangladesh is the poorest to have a total fertility rate under 5 births/woman. Only Vietnam has a fertility level similar to Bangladeshs at a comparably low per capita income but its per capita purchasing power is 60% higher its mortality is much lower and its family planning program is somewhat coercive. A World Bank study on the determinants of reproductive change in Bangladesh determined that no change was needed in the levels of economic development urbanization womens employment or education for the family planning program to succeed. Rather sustained political commitment at the highest levels to an effective family planning program was the key to Bangladeshs successful fertility transition. The authors investigated whether the experimental conditions of the Bank study were good enough to warrant the findings. Data were drawn from Bangladesh statistical information and a joint research program on fertility decline conducted by the Extension Project of the International Center for Diarrheal Disease Research Bangladesh and the Australian National University.

Evidence-based approaches to childhood stunting in low and middle income countries: a systematic review

Abstract: Objective We systematically evaluated health and nutrition programmes to identify context-specific interventional packages that might help to prioritise the implementation of programmes for reducing stunting in low and middle income countries (LMICs). Methods Electronic databases were used to systematically review the literature published between 1980 and 2015. Additional articles were identified from the reference lists and grey literature. Programmes were identified in which nutrition-specific and nutrition-sensitive interventions had been implemented for children under 5 years of age in LMICs. The primary outcome was a change in stunting prevalence, estimated as the average annual rate of reduction (AARR). A realist approach was applied to identify mechanisms underpinning programme success in particular contexts and settings. Findings Fourteen programmes, which demonstrated reductions in stunting, were identified from 19 LMICs. The AARR varied from 0.6 to 8.4. The interventions most commonly implemented were nutrition education and counselling, growth monitoring and promotion, immunisation, water, sanitation and hygiene, and social safety nets. A programme was considered to have effectively reduced stunting when AARR≥3%. Successful interventions were characterised by a combination of political commitment, multi-sectoral collaboration, community engagement, community-based service delivery platform, and wider programme coverage and compliance. Even for similar interventions the outcome could be compromised if the context differed. Interpretation For all settings, a combination of interventions was associated with success when they included health and nutrition outcomes and social safety nets. An effective programme for stunting reduction embraced country-level commitment together with community engagement and programme context, reflecting the complex nature of exposures of relevance. PROSPERO registration number CRD42016043772.

Evaluation of rapid diagnostic tests: visceral leishmaniasis

Abstract: Visceral leishmaniasis (VL) is a severe infectious disease caused by a protozoan parasite: Leishmania donovani in East Africa and the Indian subcontinent and Leishmania infantum in Latin America and the Mediterranean basin. Not all leishmanial infections lead to overt clinical disease, but in those infected persons who do develop the disease, multiplication of the parasite in the reticulo-endothelial system causes prolonged fever, anaemia, hepatosplenomegaly and weight loss. VL is fatal if it is not adequately treated. The drugs currently used to treat VL can have severe side effects and the clinical presentation of VL is not sufficiently specific to guide treatment. Highly accurate (both sensitive and specific), cheap and simple rapid diagnostic tests (RDTs) are therefore crucial for case-management of VL. Early case detection followed by adequate treatment is also central to control of VL because, as yet, no vaccine is available and the long-term impact of vector control is unclear. Although the need for accurate VL diagnostics is obvious, innovation in this field has been slow. Since the 1980s, the main objective of VL diagnostics development has been to replace the direct demonstration of parasites in tissue smears, a technique that is invasive and requires considerable expertise, by a ‘field test’ that is more appropriate for use in a VL-endemic context. Several serological tests have been developed, but none are specific for VL disease as such, although they have proved useful in combination with a clinical case definition. New diagnostic tools are needed for more than just the confirmation of VL disease. No alternatives to parasitological methods are yet available to establish test of cure in treated VL patients. Clinicians do not have the tools to distinguish re-infection from relapse in cases of recurrence, and control programmes do not have validated assays for the surveillance of drug resistance in parasites. Furthermore, in the context of the VL elimination initiative, it would be desirable to have better markers of leishmanial infection at the population level. Any evaluation of a new diagnostic device should carefully identify its intended purpose. Too often developers and researchers confuse a device for the detection of leishmanial infection with a device for the confirmation of VL disease, and this is particularly the case for nucleic-acidbased assays. PCR is usually highly sensitive for detection of leishmanial infection, but this does not mean PCR will be useful for the confirmation of acute VL disease in patients in endemic areas, as many carriers of the infection in these areas will be PCRpositive without developing VL disease. This article will focus specifically on the evaluation of RDTs for confirmation of VL disease.